


Application No. 10/789,817  
 Babish, John G.  
 Filed: February 27, 2004

RECEIVED  
 CENTRAL FAX CENTER

DEC 18 2007

**THE CLAIMS:**

1. (Previously presented) A composition comprising a compound selected from the group consisting of reduced isoalpha acids, tetra-hydroisoalpha acids, and hexa-hydroisoalpha acids; and a methylxanthine.
2. (Previously presented) The composition of claim 1, wherein the compound selected from the group consisting of reduced isoalpha acids, tetra-hydroisoalpha acids, and hexa-hydroisoalpha acids is derived from hops.
3. (Previously presented) The composition of claim 1, wherein the compound selected from the group consisting of reduced isoalpha acids, tetra-hydroisoalpha acids, and hexa-hydroisoalpha acids comprises a member of a supragenus having the formula:



wherein R' is selected from the group consisting of carbonyl, hydroxyl, OR, and OCOR, wherein R is alkyl;

wherein R'' is selected from the group consisting of  $\text{CH}(\text{CH}_3)_2$ ,  $\text{CH}_2\text{CH}(\text{CH}_3)_2$ , and  $\text{CH}(\text{CH}_3)\text{CH}_2\text{CH}_3$ ;


and wherein R, T, X, and Z are independently selected from the group consisting of H, F, Cl, Br, I, and  $\pi$  orbital, with the proviso that if one of R, T, X, or Z is a  $\pi$  orbital, then the adjacent R, T, X, or Z is also a  $\pi$  orbital, thereby forming a double bond.

(2)

BST99 1560466-1.068911.0074

Application No. 10/789,817  
Babish, John G.  
Filed: February 27, 2004

4. (Previously presented) The composition of claim 1, wherein said compound selected from the group consisting of reduced isoalpha acids, tetra-hydroisoalpha acids, and hexa-hydroisoalpha acids comprises a member of Genus A having the formula:




(Genus A),

wherein R' is selected from the group consisting of carbonyl, hydroxyl, OR, and OCOR, wherein R is alkyl;

and wherein R" is selected from the group consisting of CH(CH<sub>3</sub>)<sub>2</sub>, CH<sub>2</sub>CH(CH<sub>3</sub>)<sub>2</sub>, and CH(CH<sub>3</sub>)CH<sub>2</sub>CH<sub>3</sub>.

5. (Previously presented) The composition of claim 1, wherein the compound selected from the group consisting of reduced isoalpha acids, tetra-hydroisoalpha acids, and hexa-hydroisoalpha acids comprises a member of Genus B having the formula:



(Genus B),

wherein R' is selected from the group consisting of carbonyl, hydroxyl, OR, and OCOR, wherein R is alkyl;

and wherein R" is selected from the group consisting of CH(CH<sub>3</sub>)<sub>2</sub>, CH<sub>2</sub>CH(CH<sub>3</sub>)<sub>2</sub>, and CH(CH<sub>3</sub>)CH<sub>2</sub>CH<sub>3</sub>.

(3)

BST99 1560466-1.068911.0074

Application No. 10/789,817

Babish, John G.

Filed: February 27, 2004

6. (Previously presented) The composition of claim 1, wherein said compound selected from the group consisting of reduced isoalpha acids, tetra-hydroisoalpha acids, and hexa-hydroisoalpha acids comprises a member selected from the group consisting of dihydro-isohumulone, dihydro-isocohumulone, dihydro-adhumulone, tetrahydro-isohumulone, tetrahydro-isocohumulone, tetrahydro-adhumulone, hexahydro-isohumulone, hexahydro-isocohumulone, and hexahydro-adhumulone.

7. (Original) The composition of claim 1, wherein said methylxanthine is selected from caffeine; theobromine; theophylline; aminophylline; doxophylline; pentoxifylline; 8-oxopentoxifylline; 8-oxolosofylline; lisofylline; 1-proparagyl 3,7-dimethyl xanthine; 7-proparagyl 1,3-dimethyl xanthine; 3-proparagyl 1,7-dimethyl xanthine; 1,3,7-tripropyl xanthine; 3-isobutyl-1-methylxanthine (IBMX); 1,3,7-tripropyl xanthine; 7-benzyl-IBMX; 1-propyl 3,7-dimethyl xanthine; 1,3-dipropyl 7-methyl xanthine; 1,3-dipropyl 7-proparagyl xanthine; 3,7-dimethyl 1-propyl xanthine; and 7-allyl 1,3-dimethyl xanthine.

8. (Previously presented) The composition of claim 1, wherein the compound selected from the group consisting of reduced isoalpha acids, tetra-hydroisoalpha acids, and hexa-hydroisoalpha acids; and methylxanthine are in a ratio of about 100:1 to about 1:100.

9. (Previously presented) The composition of claim 8, wherein the methylxanthine is caffeine.

10. (CURRENTLY AMENDED) The composition of claim 1, wherein the composition comprises about 0.5 to 10000 mg of said compound selected from the group consisting of reduced isoalpha acids, tetra-hydroisoalpha acids, and hexa-hydroisoalpha acids.

11. (Previously presented) The composition of claim 10, wherein the composition comprises about 50 to 7500 mg of the compound selected from the group consisting of reduced isoalpha acids, tetra-hydroisoalpha acids, and hexa-hydroisoalpha acids.

12. (Previously presented) The composition of claim 1, wherein the composition comprises about 0.001 to 10 weight percent of the compound selected from the group

(4)

BST99 1560466-1.068911.0074

Application No. 10/789,817  
Babish, John G.  
Filed: February 27, 2004

consisting of reduced isoalpha acids, tetra-hydroisoalpha acids, and hexa-hydroisoalpha acids.

13. (Previously presented) The composition of claim 12, wherein the composition comprises about 0.1 to 1 weight percent of the compound selected from the group consisting of reduced isoalpha acids, tetra-hydroisoalpha acids, and hexa-hydroisoalpha acids.


14. (ORIGINAL) The composition of claim 1, wherein the composition further comprises a pharmaceutically acceptable carrier.

15. (ORIGINAL) The composition of claim 1, wherein the composition is formulated for administration orally, topically, parenterally, or rectally.

16. (Withdrawn) A composition comprising a compound selected from the group consisting of reduced isoalpha acids, tetra-hydroisoalpha acids, and hexa-hydroisoalpha acids; and a curcuminoid.

17. (Withdrawn) The composition of claim 16, wherein the compound selected from the group consisting of reduced isoalpha acids, tetra-hydroisoalpha acids, hexa-hydroisoalpha acids is derived from hops.

18. (Withdrawn) The composition of claim 16, wherein the compound selected from the group consisting of reduced isoalpha acids, tetra-hydroisoalpha acids, and hexa-hydroisoalpha acids comprises a member of a supragenus having the formula:



wherein R' is selected from the group consisting of carbonyl, hydroxyl, OR, and OCOR,  
wherein R is alkyl;

(5)


BST99 1560468-1.068911.0074

Application No. 10/789,817  
 Babish, John G.  
 Filed: February 27, 2004

wherein R" is selected from the group consisting of CH(CH<sub>3</sub>)<sub>2</sub>, CH<sub>2</sub>CH(CH<sub>3</sub>)<sub>2</sub>, and CH(CH<sub>3</sub>)CH<sub>2</sub>CH<sub>3</sub>;

and wherein R, T, X, and Z are independently selected from the group consisting of H, F, Cl, Br, I, and π orbital, with the proviso that if one of R, T, X, or Z is a π orbital, then the adjacent R, T, X, or Z is also a π orbital, thereby forming a double bond.

19. (Withdrawn) The composition of claim 16, wherein said compound selected from the group consisting of reduced isoalpha acids, tetra-hydroisoalpha acids, and hexa-hydroisoalpha acids comprises a member of Genus A having the formula:




(Genus A),

wherein R' is selected from the group consisting of carbonyl, hydroxyl, OR, and OCOR, wherein R is alkyl;

and wherein R" is selected from the group consisting of CH(CH<sub>3</sub>)<sub>2</sub>, CH<sub>2</sub>CH(CH<sub>3</sub>)<sub>2</sub>, and CH(CH<sub>3</sub>)CH<sub>2</sub>CH<sub>3</sub>.

20. (Withdrawn) The composition of claim 16, wherein the compound selected from the group consisting of reduced isoalpha acids, tetra-hydroisoalpha acids, and hexa-hydroisoalpha acids comprises a member of Genus B having the formula:



wherein R' is selected from the group consisting of carbonyl, hydroxyl, OR, and OCOR,  
 (6)

BST99 1560466-1.088911.0074

Application No. 10/789,817  
Babish, John G.  
Filed: February 27, 2004

wherein R is alkyl;

and wherein R" is selected from the group consisting of CH(CH<sub>3</sub>)<sub>2</sub>, CH<sub>2</sub>CH(CH<sub>3</sub>)<sub>2</sub>, and CH(CH<sub>3</sub>)CH<sub>2</sub>CH<sub>3</sub>.

21. (Withdrawn) The composition of claim 16, wherein said compound selected from the group consisting of reduced isoalpha acids, tetra-hydroisoalpha acids, and hexa-hydroisoalpha acids comprises a member selected from the group consisting of dihydro-adhumulone, tetrahydro-isohumulone, tetrahydro-isocohumulone, tetrahydro-adhumulone, hexahydro-isohumulone, hexahydro-isocohumulone, and hexahydro-adhumulone.

22. (Withdrawn) The composition of claim 16, wherein said curcuminoid is selected from curcumin, demethoxycurcumin, bisdemethoxycurcumin, cis-trans-curcumin and cyclocurcumin.

23. (Withdrawn) The composition of claim 16, wherein the compound selected from the group consisting of reduced isoalpha acids, tetra-hydroisoalpha acids, and hexa-hydroisoalpha acids and the curcuminoid are in a ratio of about 100:1 to about 1:10.

24. (Withdrawn) The composition of claim 23, wherein the ratio is about 3:2.

25. (Withdrawn) The composition of claim 24, wherein the curcuminoid is curcumin.

26. (Withdrawn) The composition of claim 16, wherein the composition comprises about 0.5 to 10000 mg of said compound selected from the group consisting of reduced isoalpha acids, tetra-hydroisoalpha acids, and hexa-hydroisoalpha acids.

27. (Withdrawn) The composition of claim 26, wherein the composition comprises about 50 to 7500 mg of the compound selected from the group consisting of reduced isoalpha acids, tetra-hydroisoalpha acids, and hexa-hydroisoalpha acids.

28. (Withdrawn) The composition of claim 16, wherein the composition comprises about 0.001 to 10 weight percent of the compound selected from the group consisting of reduced isoalpha acids, tetra-hydroisoalpha acids, and hexa-hydroisoalpha acids.

(7)

BST99 1560466-1.068911.0074

Application No. 10/789,817  
Babish, John G.  
Filed: February 27, 2004

29. (Withdrawn) The composition of claim 28, wherein the composition comprises about 0.1 to 1 weight percent of the compound selected from the group consisting of reduced isoalpha acids, tetra-hydroisoalpha acids, and hexa-hydroisoalpha acids.

30. (Withdrawn) The composition of claim 16, wherein the composition further comprises a pharmaceutically acceptable carrier.

31. (Withdrawn) The composition of claim 16, wherein the composition is formulated for administration orally, topically, parenterally, or rectally.

32. (Previously presented) A method of reducing inflammation, comprising administering a composition of any of claims 1-31.

(8)

BST99 1560466-1.068911.0074

PAGE 11/13 \* RCVD AT 12/18/2007 4:03:38 PM [Eastern Standard Time] \* SVR:USPTO-EFXRF-6/17 \* DNIS:2738300 \* CSID:617 535 3869 \* DURATION (mm:ss):03:44